Modeling the Health and Economic Implications of Adopting a 1-dose 9-valent Human Papillomavirus Vaccination Program in Adolescents in Low/middle-income Countries: An Analysis of Indonesia

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Nov 21

PMID 39570910

Authors

Vincent Daniels

Kunal Saxena

Oscar Patterson-Lomba

Andres Gomez-Lievano

Jarir At Thobari

Nancy Durand

Evan Myers

Affiliations

Soon will be listed here.

Abstract

Background: Recent evidence suggests that 1 dose of the human papillomavirus (HPV) vaccine may have similar effectiveness in reducing HPV infection risk compared to 2 or 3 doses.

Objective: To evaluate the public health impact and cost-effectiveness of implementing a 1-dose or a 2-dose program of the 9-valent HPV vaccine in a low- and middle-income country (LMIC).

Methods: We adapted a dynamic transmission model to the Indonesia setting, and conducted a probabilistic sensitivity analysis using distributions reflecting the uncertainty in levels and durability of protection of a 1-dose that were estimated under a Bayesian framework incorporating 3-year vaccine efficacy data from the KEN SHE trial (base-case) and 10 year effectiveness data from the India IARC study (alternative analysis). Scenarios included different coverage levels targeted at girls-only, or girls and boys. Costs and benefits were computed over 100 years from a national single-payer perspective.

Results: Depending on the coverage and target population, the median number of cancer cases avoided in 2-dose programs ranged between 600,000-2,100,000, compared to 200,000-600,000 in 1-dose programs. The 1-dose programs are unlikely to be cost-effective compared to 2-dose programs even at low willingness-to-pay (WTP) thresholds. The girls-only 2-dose program tends to be cost-effective at lower WTP thresholds, particularly in scenarios with high coverage, dose price and discount rate, while the girls and boys 2-dose program is cost-effective at higher WTP thresholds. In the alternative analysis, 1-dose programs have higher probability of being cost-effective compared to the base-case, particularly for low WTP thresholds (less than 0.5 GDP) and for high coverage, dose price and discount rate.

Conclusion: Adoption of 1-dose programs with 9-valent vaccine in an LMIC resulted in more vaccine-preventable HPV-related cancer cases than 2-dose programs. The 2-dose programs were more likely to be cost-effective than 1-dose programs for a wide range of WTP thresholds and scenarios.

References

Barnabas R, Brown E, Onono M, Bukusi E, Njoroge B, Winer R . Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. Trials. 2021; 22(1):661. PMC: 8475401. DOI: 10.1186/s13063-021-05608-8. View

Zeng Y, Moscicki A, Woo H, Hsu C, Kemp T, Pinto L . HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine. Pediatrics. 2023; 152(1). PMC: 10312231. DOI: 10.1542/peds.2022-060301. View

Baisley K, Kemp T, Kreimer A, Basu P, Changalucha J, Hildesheim A . Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial. Lancet Glob Health. 2022; 10(10):e1485-e1493. PMC: 9638025. DOI: 10.1016/S2214-109X(22)00306-0. View

Kreimer A, Herrero R, Sampson J, Porras C, Lowy D, Schiller J . Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018; 36(32 Pt A):4774-4782. PMC: 6054558. DOI: 10.1016/j.vaccine.2017.12.078. View

Luxembourg A, Moeller E . 9-Valent human papillomavirus vaccine: a review of the clinical development program. Expert Rev Vaccines. 2017; 16(11):1119-1139. DOI: 10.1080/14760584.2017.1383158. View

Rodriguez A, Zeybek B, Vaughn M, Westra J, Kaul S, Montealegre J . Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer. 2020; 126(8):1656-1667. DOI: 10.1002/cncr.32700. View

Kreimer A, Sampson J, Porras C, Schiller J, Kemp T, Herrero R . Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst. 2020; 112(10):1038-1046. PMC: 7566548. DOI: 10.1093/jnci/djaa011. View

Owusu-Edusei K, Palmer C, Ovcinnikova O, Favato G, Daniels V . Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom. J Health Econ Outcomes Res. 2022; 9(1):140-150. PMC: 9170517. DOI: 10.36469/001c.34721. View

Ault K . Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369(9576):1861-1868. DOI: 10.1016/S0140-6736(07)60852-6. View

10.

Pingali C, Yankey D, Elam-Evans L, Markowitz L, Valier M, Fredua B . National Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(35):1101-1108. PMC: 9472778. DOI: 10.15585/mmwr.mm7135a1. View

11.

Barnabas R, Brown E, Onono M, Bukusi E, Njoroge B, Winer R . Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat Med. 2023; 29(12):3224-3232. PMC: 10719107. DOI: 10.1038/s41591-023-02658-0. View

12.

Velicer C, Luxembourg A, Chen Y, Kohn M, Saah A . Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection. Vaccine. 2022; 40(24):3275-3277. DOI: 10.1016/j.vaccine.2022.04.088. View

13.

de Sanjose S, Serrano B, Tous S, Alejo M, Lloveras B, Quiros B . Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2019; 2(4):pky045. PMC: 6649711. DOI: 10.1093/jncics/pky045. View

14.

Garland S, Hernandez-Avila M, Wheeler C, Perez G, Harper D, Leodolter S . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-43. DOI: 10.1056/NEJMoa061760. View

15.

Drolet M, Laprise J, Martin D, Jit M, Benard E, Gingras G . Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infect Dis. 2021; 21(11):1598-1610. PMC: 8554391. DOI: 10.1016/S1473-3099(20)30860-4. View

16.

Burger E, Campos N, Sy S, Regan C, Kim J . Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine. 2018; 36(32 Pt A):4823-4829. PMC: 6066173. DOI: 10.1016/j.vaccine.2018.04.061. View

17.

Whitworth H, Gallagher K, Howard N, Mounier-Jack S, Mbwanji G, Kreimer A . Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. 2019; 38(6):1302-1314. DOI: 10.1016/j.vaccine.2019.12.017. View

18.

Batmunkh T, Dalmau M, Munkhsaikhan M, Khorolsuren T, Namjil N, Surenjav U . A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Vaccine. 2020; 38(27):4316-4324. PMC: 7254061. DOI: 10.1016/j.vaccine.2020.04.041. View

19.

Brisson M, Kim J, Canfell K, Drolet M, Gingras G, Burger E . Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020; 395(10224):575-590. PMC: 7043009. DOI: 10.1016/S0140-6736(20)30068-4. View

20.

Hariri S, Schuler M, Naleway A, Daley M, Weinmann S, Crane B . Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States. Am J Epidemiol. 2017; 187(2):298-305. DOI: 10.1093/aje/kwx253. View